We noticed you’re blocking ads

Thanks for visiting CRSToday. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

In order to avoid adverse performance issues with this site, please white list https://crstoday.com in your ad blocker then refresh this page.

Need help? Click here for instructions.

Innovations | Aug 2003

Innovations

OThe FDA recently approved the ACRYSOF Natural Single-Piece IOL (Alcon Laboratories, Inc., Fort Worth, TX), which filters UV and high-energy blue light. The lens is composed entirely of Alcon's ACRYSOF lens material and features a covalently bound chromophore that provides filtration of blue light between 400 and 500 nm. According to the company, the ACRYSOF Natural IOL provides clear vision and preserves the protective benefits of the natural crystalline lens. The lens has a 6-mm optic diameter and a 13-mm overall diameter. Alcon plans to launch the lens this month.

Price: N/A
Company: Alcon Laboratories, Inc.
Phone: (800) 757-9195
Web: www.alconlabs.com
Key Features
• First foldable UV and blue-light–filtering IOL approved in US
• Proprietary blue-light–absorbing chromophore
• 6-mm optic diameter; 13-mm overall diameter

Marco 3-D System
Marco (Jacksonville, FL) has added the 3-D System to its Vision Diagnostics product line. The 3-D System combines three advanced technologies: corneal topography, zonal refraction, and autorefraction/keratometry in one compact unit. The company states that this device can create detailed corneal analysis that previously would require at least two tests using two different instruments. The 3-D System allows the doctor to evaluate patients for refractive screenings, pathology detection, and contact lens fittings. n

Price: N/A
Company: Marco
Phone: (800) 874-5274
Web: www.marcooph.com
Key Features
• Zonal refraction
• Corneal topographer
• Automatic refractor and keratometer
Advertisement - Issue Continues Below
Publication Ad Publication Ad
End of Advertisement - Issue Continues Below

NEXT IN THIS ISSUE